A3P Biomedicals leading product is Stockholm3, a clinically and commercially validated blood test for early detection of aggressive prostate cancer. The company has also a new blood test in pipeline, aimed to identify biomarkers in men with metastatic prostate cancer.
“We will increase the detection of aggressive cases of cancer while reducing the number of men who have to undergo unnecessary, painful and often expensive follow-ups.” Henrik Grönberg, Professor of cancer epidemiology at Karolinska Institutet, Stockholm
Nearly 1.4 million men are estimated to be diagnosed with prostate cancer in 2020. Prostate cancer is the second most common cancer in the world and the 5th leading cause of cancer deaths among men. More than 350,000 men are estimated to die during 2020. In Sweden prostate cancer is the most common cancer of all. More than 10,000 men are yearly diagnosed, approximately 2,300 dies every year. SOURCE: WHO and Cancerfonden